Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Large B-Cell, Diffuse × navitoclax × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 7 Primary Myelofibrosis 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Solid Tumors 4 Lymphoma 3 Leukemia, Myeloid, Acute 3 Recurrence 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Lymphoma, Non-Hodgkin 2 Leukemia, B-Cell 2 Leukemia 2 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Prostatic Neoplasms 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Mycosis Fungoides 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1

Interventions

Rituximab 342 Cyclophosphamide 303 Vincristine 149 Prednisone 147 Doxorubicin 145 Etoposide 141 Filgrastim 96 Peripheral Blood Stem Cell Transplantation 90 Lenalidomide 88 fludarabine phosphate 73 Radiotherapy 68 Cytarabine 65 Gemcitabine 63 Methotrexate 51 Mycophenolic Acid 50 Cyclosporine 50 Melphalan 49 Ifosfamide 47 fludarabine 45 Busulfan 45 Carmustine 44 Whole-Body Irradiation 40 Oxaliplatin 40 Tacrolimus 38 Carboplatin 38 Antilymphocyte Serum 34 polatuzumab vedotin 33 Magnetic Resonance Spectroscopy 33 Dexamethasone 33 Bendamustine Hydrochloride 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01423539 2016-11-02

NAVIGATE

Genentech, Inc.

Phase 2 Withdrawn

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡